Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Subscribe To Our Newsletter & Stay Updated
